PortfoliosLab logo
Bone Biologics Corporation (BBLG)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US0980703039

CUSIP

098070303

IPO Date

Mar 31, 2016

Highlights

Market Cap

$2.45M

EPS (TTM)

-$4.83

EBITDA (TTM)

-$4.22M

Year Range

$0.57 - $3.70

Target Price

$16.50

Short %

2.92%

Short Ratio

1.64

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Bone Biologics Corporation (BBLG) returned -22.34% year-to-date (YTD) and -61.97% over the past 12 months.


BBLG

YTD

-22.34%

1M

-1.30%

6M

-44.68%

1Y

-61.97%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.64%

1M

8.97%

6M

-2.62%

1Y

11.90%

5Y*

15.76%

10Y*

10.69%

*Annualized

Monthly Returns

The table below presents the monthly returns of BBLG, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202518.05%-19.94%-9.98%-15.89%8.52%-22.34%
2024-19.69%-32.51%-13.06%-26.69%6.31%-26.51%77.05%-35.19%52.14%-36.62%-9.63%-22.93%-79.20%
202334.76%4.25%-12.25%0.58%-34.81%-71.88%-10.49%-47.11%4.89%-26.07%-22.10%38.14%-91.02%
2022-39.20%-14.95%52.75%-21.58%-27.29%-11.67%-8.57%4.69%-21.64%-57.14%-33.36%-30.08%-94.04%
2021-1.77%-27.40%-3.03%-30.84%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BBLG is 32, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BBLG is 3232
Overall Rank
The Sharpe Ratio Rank of BBLG is 3232
Sharpe Ratio Rank
The Sortino Ratio Rank of BBLG is 4949
Sortino Ratio Rank
The Omega Ratio Rank of BBLG is 4848
Omega Ratio Rank
The Calmar Ratio Rank of BBLG is 1111
Calmar Ratio Rank
The Martin Ratio Rank of BBLG is 2020
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Bone Biologics Corporation (BBLG) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Bone Biologics Corporation Sharpe ratios as of May 13, 2025 (values are recalculated daily):

  • 1-Year: -0.33
  • All Time: -0.59

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Bone Biologics Corporation compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Bone Biologics Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Bone Biologics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bone Biologics Corporation was 99.95%, occurring on Apr 28, 2025. The portfolio has not yet recovered.

The current Bone Biologics Corporation drawdown is 99.94%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.95%Nov 2, 2021874Apr 28, 2025
-12.77%Oct 14, 20219Oct 26, 20214Nov 1, 202113

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Bone Biologics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Bone Biologics Corporation, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 26.2% positive surprise.


-50.00-40.00-30.00-20.00-10.000.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-0.48
-0.65
Actual
Estimate

Valuation

The Valuation section provides an overview of how Bone Biologics Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for BBLG compared to other companies in the Medical Devices industry. BBLG currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BBLG relative to other companies in the Medical Devices industry. Currently, BBLG has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BBLG in comparison with other companies in the Medical Devices industry. Currently, BBLG has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items